AAVantgarde Bio AAVantgarde Bio has two proprietary, AAV-based large gene delivery platforms. The first leveraging DNA recombination, named dual hybrid; and the second, a protein trans-splicing, named AAV intein.
Aiolos Bio Aiolos is focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions.
Amphista Therapeutics Amphista Therapeutics is a leading European targeted protein degradation (TPD) company.
Anaveon Anaveon is a clinical stage, biopharmaceutical company that develops biologics to modulate the function of cytokines and provide substantial therapeutic benefit to cancer patients.
ARMGO Pharma ARMGO is a clinical-stage therapeutic company developing ARM210, an oral treatment for cardiac, musculoskeletal and neurological diseases.
Azafaros Azafaros aims to be a beacon of hope for patients living with severe rare genetic diseases and their families.
BioInvent BioInvent is a clinical stage company focused on the development of novel, first-in-class immuno-modulatory antibodies for the treatment of cancer.
Calluna Pharma Calluna Pharma is a clinical stage company developing therapies for inflammatory and fibrotic diseases
Capstan Therapeutics Capstan’s mission is to multiply the therapeutic possibilities for patients by developing targeted in vivo RNA-based therapies.
Covicept Therapeutics Oral antiviral drug therapies to provide treatments against the 2019 novel coronavirus (COVID-19) and other pandemic RNA viruses.
Dyne Therapeutics Dyne focuses on transforming the lives of people with serious muscle diseases by pioneering muscle-targeted therapies.
enGene Development of gene therapy targeting mucosal tissues, including those of the bladder, lung and gut.
Engrail Therapeutics Engrail Therapeutics is a clinical-stage pharmaceutical company founded in 2019 with the aspiration of becoming a leader in neuroscience. The company is committed to rapidly advancing its innovative, precision-targeted therapeutics.
Enterprise Therapeutics A biopharmaceutical company dedicated to the research and development of novel therapies for the treatment of respiratory diseases.
Escalier Biosciences Escalier Biosciences develops oral RORγt-based therapeutics for treatment of psoriasis and other autoimmune diseases
F2G F2G is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat life-threatening invasive fungal infections.
Inversago Pharma Pioneering the development of first-in-class, peripherally-acting, CB1 inverse agonists
Kynexis Kynexis is advancing precision therapeutics for brain diseases by taking a biomarker-based approach to advance a potential first-in-class treatment for cognitive impairment associated with schizophrenia (CIAS).
Mariana Oncology Mariana Oncology creates medicines to treat tumors by harnessing the power of precisely-delivered radiation.
Mestag Therapeutics Mestag Therapeutics discovers, develops and delivers impactful precision medicines into disease-driving fibroblast subpopulations.
NewAmsterdam Pharma NewAmsterdam Pharma is a clinical stage company focused on the research and development of transformative therapies for cardio-metabolic diseases
Noema Pharma Noema Pharma's pipeline contains novel therapies designed to address debilitating central nervous system (CNS) disorders in order to improve quality of life and patient outcomes.
NorthSea Therapeutics NorthSea Therapeutics develops therapeutics for NASH and other metabolic, inflammatory and fibrotic diseases.
OMEICOS Developing a novel class of synthetic lipid mediators for the treatment of cardiovascular and ophthalmic diseases.
Orbis Medicines Orbis’ platform is the first to systematically explore the macrocycle chemical space using a unique combination of high-throughput chemical synthesis and large-scale assaying, supported by machine learning
Pheon Therapeutics Pheon Therapeutics is a leading Antibody-Drug Conjugate (ADC) specialist developing next generation ADCs for a wide range of hard-to-treat cancers
Rampart Bio Rampart Bioscience is developing a new generation of genetic therapies leveraging its proprietary DNA-based medicines platform.
Rectify Pharma Developing disease-modifying precision therapeutics for patients with serious genetic diseases
Seamless Seamless Therapeutics is changing the paradigm of gene editing through a pioneering approach of reprogramming recombinases.
SynOx Therapeutics Addressing the unmet clinical needs of patients with Tenosynovial Giant Cell Tumours (TGCT)
VectivBio VectivBio AG is a global, clinical-stage biotechnology company developing innovative treatments for severe rare conditions with significant unmet medical need.
VectorY An integrated gene therapy company focused on the development of innovative therapeutics such as vectorized antibodies for CNS diseases.
Versanis Bio Versanis is progressing a first-in-class therapy to address one of the most prevalent and urgent chronic disease epidemics of our time.
Abiomed Developing ground-breaking technologies designed to assist or replace the life-sustaining pumping function of the failing heart.
Acadia Pharmaceuticals Innovative treatments that address unmet medical needs in neurological and related central nervous system disorders.
Alantos Pharmaceuticals Developing small molecule drugs for Type II diabetes and Osteoarthritis/inflammation based diseases.
Ardana Combined an in-licencing and M&A driven strategy to commercialize research carried out by the MRC and HRSU.
Bioceros Biotech company offering services on early pre-clinical development of recombinant proteins.
Bluebird Bio Innovative gene therapies for severe genetic disorders from a broadly applicable gene therapy platform.
Borean Pharma Identifying and producing low cost molecular binders based on naturally occurring human protein.
Curetis Simple and rapid solutions for the diagnosis of severe infectious diseases in hospitalized patients.
Cytheris Developing a human recombinant IL-7 for the treatment of diseases that are caused by lymphopenia.
Exosome Diagnostics Revolutionary, biofluid-based diagnostics to deliver personalized precision healthcare
Flowmedica Novel, proprietary, minimally invasive intravascular systems for implementing targeted renal therapy.
Forbion European Acquisition Corporation The Forbion European Acquisition Corporation (FEAC) is an entity integrated into the Forbion Growth Fund and is fully part of the fund’s portfolio.
Gotham Therapeutics Gotham Therapeutics has assembled an exceptional team and network to establish a novel drug class targeting the epitranscriptomics machinery.
Impella Cardiosystems Developed a small ventricular assist device for temporary support in hospital setting.
Inflazome Developing inflammasome inhibitors for the treatment of age-related and orphan inflammatory diseases
Milestone Pharmaceuticals, Inc. Developing fast-acting intranasal drugs to resolve cardiac rhythm disorders
Oxitope Dedicated to the discovery and development of medicines for the treatment of inflammatory and cardiovascular diseases caused by oxidative stress
Pathway Medical Technologies Developed innovative medical devices for the treatment of arterial diseases.
Pieris Pharmaceuticals Developing Anticalin® product candidates to help patients suffering from cancer, severe asthma, anemia and other medical conditions with a high unmet medical need.
Rigontec Harnessing one of the most essential pathways in the innate immune system to generate effective therapies.
X-Cell Medical Developing next-generation solutions for restenosis and other cardiovascular clinical applications.